FDA clears Masimo smartSET atrial fibrillation detection capability for Radius VSM patient monitoring system
The FDA has cleared Masimo's smartSET-powered atrial fibrillation detection capability for the Radius VSM patient monitoring system, expanding its continuous monitoring functionality.
The newly cleared capability uses advanced pulse oximetry signal analysis to help clinicians identify patterns associated with atrial fibrillation during patient monitoring.
Masimo's announcement also references opioid-induced respiratory depression detection, but that functionality received FDA clearance in June 2026 and is separate from the newly reportable AFib clearance.
Field | Content |
Article Type | Approvals |
Device Name | Radius VSM |
Technology Name | smartSET |
Company | Masimo |
Regulatory Authority | U.S. Food and Drug Administration |
Regulatory Decision | 510(k) clearance |
Newly Cleared Capability | Atrial fibrillation detection |
Device Category | Continuous patient monitoring system |
Underlying Technology | Advanced pulse oximetry signal analysis |
Clinical Application | Detection of signal patterns associated with atrial fibrillation during patient monitoring |
Therapeutic Area | Cardiovascular monitoring; medical technology |
Target Condition | Atrial fibrillation |
Platform | Masimo Radius VSM |
Clinical Function | Support clinician recognition of patterns associated with atrial fibrillation |
Approval Announcement Date | 17 October 2026 |
Geography | United States |
Related Capability | Opioid-induced respiratory depression detection |
Earlier Regulatory Milestone | Opioid-induced respiratory depression detection received FDA clearance in June 2026 |
Clinical Evidence | Specific clinical performance metrics were not provided in the supplied summary |
What Happened | The FDA granted 510(k) clearance for Masimo's smartSET-powered atrial fibrillation detection capability on the Radius VSM patient monitoring platform. |
Why It Matters | The clearance expands the clinical monitoring functions available through Masimo's technology and may help clinicians recognise potential atrial fibrillation during continuous monitoring. |
Supporting Context | The newly cleared AFib functionality is distinct from the previously cleared opioid-induced respiratory depression detection feature. |
Potential Impact | The expanded capability could support broader use of continuous monitoring technology in clinical settings where recognition of cardiac rhythm abnormalities is important. |
Regulatory Context | Medical device clearance rather than pharmaceutical marketing authorisation |
Key Takeaway | Masimo has secured a new FDA clearance for atrial fibrillation detection using smartSET technology on Radius VSM; its opioid-related monitoring clearance dates to June 2026. |
What to Watch | Commercial availability, hospital adoption, integration into clinical monitoring workflows, clinical performance evidence and future regulatory developments. |
Primary Source | Masimo |
Primary Source URL | https://www.masimo.com/media/masimos-smartset-tm-fda-clearance-offers-breakthrough-innovation-in-pulse-oximetry-to-help-improve-critical-patient-outcomes |
Relevant Date | 17 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글